Emulsions for ocular applications containing semifluorinated alkanes

Stable emulsions combining semifluorinated alkanes and aqueous phases with a low surfactant content address the instability issue, offering a single treatment for both types of dry eye disease by ensuring compatibility and ease of application.

WO2026233966A1PCT designated stage Publication Date: 2026-11-12BAUSCH & LOMB IRELAND LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062882
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing ophthalmic compositions that combine semifluorinated alkanes with aqueous-based systems are unstable due to immiscibility and density differences, making it challenging to develop a single formulation suitable for treating both aqueous-deficient and evaporative dry eye disease.

Method used

The development of stable emulsions comprising an organic phase with semifluorinated alkane, an aqueous phase, and a surfactant, with a surfactant content of about 15% or less by weight, forming an oil-in-water emulsion that maintains stability and compatibility.

Benefits of technology

The emulsions provide effective treatment for both aqueous-deficient and evaporative dry eye disease, minimizing irritation and maintaining stability over time, allowing easy application and distribution on the eye.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000019_0001_TABLE
    Figure IMGF000019_0001_TABLE
  • Figure IMGF000019_0002_TABLE
    Figure IMGF000019_0002_TABLE
  • Figure IMGF000020_0001_TABLE
    Figure IMGF000020_0001_TABLE
Patent Text Reader

Abstract

Emulsions for ocular applications containing at least one semifluorinated alkane, such as F6H8, their use in methods for treating ocular disorders, and methods for their manufacture are disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

EMULSIONS FOR OCULAR APPLICATIONS CONTAINING SEMIFLUORINATED ALKANES

[0001] This application claims the benefit of European Patent Application EP25174583.2, filed May 6th 2025, the complete contents of which are incorporated herein by reference. This application also claims the benefit of United Kingdom Patent Application GB2506973.3, filed May 7th 2025, the complete contents of which are incorporated herein by reference.

[0002] The present invention relates to emulsions for ocular applications containing at least one semifluorinated alkane, such as F6H8, their use in methods for treating ocular disorders, and methods for their manufacture.BACKGROUND

[0003] Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a multifunctional disorder of the tear film and ocular surface, which results in discomfort, visual disturbance, and often even in ocular surface damage. Secondary diseases whose development may be triggered by dry eye disease include filamentary keratitis, microbial keratitis, corneal neovascularisation, and ocular surface keratinisation.

[0004] Two major categories of dry eye disease are distinguished today, which are aqueous-deficient DED and evaporative DED.

[0005] Within the class of aqueous-deficient forms of DED, two major subtypes are differentiated, Sjogren and non-Sjdgren. Evaporative DED is associated with increased evaporative loss of the tear film and can develop as a result of diverse root causes including meibomian gland disease, eyelid aperture disorders, blink disorders (as in Parkinson disease) or ocular surface disorders (as in allergic conjunctivitis).

[0006] Typically, ophthalmic compositions for treatment of ocular disorders, including DED, are administered as eye drops, with one or more drops of the composition being applied to an eye of the subject suffering from or susceptible to ocular disorders one or more times per day, although the frequency of administration of such compositions may be dependent on multiple factors, including the makeup of the particular composition.

[0007] Aqueous-deficient DED and evaporative DED are not mutually exclusive, and a large percentage of DED patients suffer from both conditions. Providing a single ophthalmic composition suitable to address both aqueous-deficient DED and evaporative DED would be of significant benefit to such patients, who may otherwise require two separate treatments, one for each type of DED.

[0008] Semifluorinated alkanes are an example of agents that may treat evaporative DED. Semifluorinated alkanes work to protect the surface of the eye by stabilizing the tear film on the surface of the eye, thereby reducing tear evaporation. Semifluorinatedalkanes have recently been approved by the FDA against evaporative DED. For example, perfluorohexyloctane (F6H8) has been approved as Miebo™ for the treatment of evaporative DED. In Miebo™, F6H8 is provided as a water-free sterile ophthalmic solution containing 100% F6H8.

[0009] For aqueous-deficient DED, aqueous based systems are established for treatment. For example, aqueous based systems comprising hydrophilic, lubricating and / or mucoadhesive polymers have shown clinical efficacy against aqueous deficient DED. Aqueous based systems are particularly suitable in the treatment of aqueous-deficient DED due to their wetting properties i.e. their ability to maintain contact with the surface of the eye. Aqueous based systems also have the ability to carry aqueous-compatible pharmaceutical actives suitable for treating DED.

[0010] It would be beneficial to combine aqueous based systems with semifluorinated alkanes, to provide ophthalmic compositions which may be suitable for treating both aqueous-deficient DED and evaporative DED. However, aqueous-based ophthalmic solutions are immiscible with semifluorinated alkanes. Semifluorinated alkanes are very hydrophobic, so do not mix well with water, meaning that mixtures of semifluorinated alkanes and water are unstable and separate readily. As a result, semifluorinated alkanes cannot be readily added to existing aqueous based systems to provide stable compositions. Additionally, semifluorinated alkanes have much higher densities than water, which creates further instability problems when attempting to mix both components in a single composition. For example, the semifluorinated alkane F6H8 has a density of 1.334 g / cm3, far higher than that of water (1 g / cm3). Currently, there is no marketed formulation that combines the effects of semifluorinated alkanes with those of aqueous based systems.

[0011] There is therefore a need for ophthalmic compositions with adequate stability that combine the benefits of semifluorinated alkanes with aqueous based systems.SUMMARY OF THE INVENTION

[0012] The invention provides an emulsion for ocular applications, comprising (a) an organic phase comprising at least one semifluorinated alkane; (b) an aqueous phase; and (c) a surfactant; wherein the emulsion comprises about 15% or less by weight of the organic phase. The semifluorinated alkane is preferably F6H8.

[0013] These and other features, aspects, and advantages of the invention will be apparent from a reading of the following.Definitions

[0014] Definitions of certain terms as used in this application are provided below. Unless defined otherwise, all technical and scientific terms used herein have the normal andcommon meaning that would be commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0015] As used herein, “a” or “an” entity refers to one or more of that entity, e.g., “a compound” refers to one or more compounds or at least one compound unless stated otherwise. As such, the terms “a” (or “an”), “one or more”, and “at least one” are used interchangeably herein.

[0016] As used herein, the term “about” means approximately, in the region of, roughly, or around. The term “about” in relation to a numerical value x is optional and means, for example, x ± 5%. Numerical values disclosed with the term “about” include the specifically identified value. For example, “about 100” means a number ranging from 95 to 105, including 95, 100, and 105.

[0017] As used herein, “administration” of a compound or composition to a patient refers to any route of introducing or delivering the compound or composition to a subject. Administration includes self-administration and the administration by another.

[0018] As used herein, a “condition,” “disorder,” or “disease” refers to any unhealthy or abnormal state.

[0019] As used herein, a composition is “free” of a component when it comprises no detectable amount of the component.

[0020] As used herein, a "surfactant" is a surface-active substance which is capable of reducing the surface tension between an organic and aqueous phase by positioning itself at the interface between these two phases. This is achieved by the amphiphilic molecular structure of the surfactant, which has at least one polar (hydrophilic) group and at least one non-polar (lipophilic) group. Thus, surfactants are soluble in both the organic and aqueous phases. The part of the surfactant that is more soluble in the organic phase projects into the organic phase, and the part of the surfactant that is more soluble in the aqueous phase projects into the aqueous phase, thus lowering the interfacial tension between the two phases.

[0021] As used herein, the term “consists essentially of” means that, in addition to the mandatory ingredients, specific further ingredients can be present, namely those not materially affecting the essential characteristics of the composition or component in question. Compositions or components herein which “consist essentially of” the specified ingredients may consist only of the specified ingredients, with no other ingredients present.

[0022] As used herein, “osmoprotectants” are small molecules that act as osmolytes and help protect cells and organisms from osmotic stress. Chemically, osmoprotectants can be divided into three types: betaines and allied compounds, polyols and sugars (e.g.glycerol, mannitol and trehalose), and amino acids. Betaines are methyl derivatives of glycine in which the nitrogen atom is fully methylated, i.e. they are quaternary ammonium compounds.

[0023] As used herein, the term "viscosity" means dynamic viscosity, which is also referred to as absolute viscosity. Unless otherwise stated, the viscosity refers to the viscosity of the composition prior to application to the eye.

[0024] As used herein, “semifluorinated alkanes” are linear or branched alkanes having fluorine in place of some of the hydrogen atoms of the corresponding non-fluorinated alkane. In particular, semifluorinated alkanes are compounds composed of at least one perfluorinated hydrocarbon segment and at least one non-fluorinated hydrocarbon segment. According to a nomenclature used herein, the semifluorinated alkanes may be referred to as FnHm, wherein F refers to the perfluorinated hydrocarbon segment (F-segment), H refers to the non-fluorinated hydrocarbon segment (H-segment), and n and m refer to the number of carbon atoms of those segments, respectively. For example, F6H8 is used to refer to perfluorohexyloctane.

[0025] This type of nomenclature is typically used for compounds wherein the perfluorinated carbons are bonded together to form a single linear F-segment and the non-fluorinated carbons are bonded together to form a single linear H-segment. Typically, the perfluorinated F-segment is attached to an end of the non-fluorinated H-segment, i.e., it is attached to C1 , so that the overall molecule is linear. However, a minority of branched compounds, wherein two linear (F and H) segments are joined at a different position such as C2, may be present. In the case of perfluorohexyloctane (F6H8), the perfluorohexyloctane comprises 95% (w / w) or more of 1 -perfluorohexyloctane, preferably 98% (w / w) or more, more preferably 99.5% (w / w) or more. Preferably, the balance is 2-perfluorohexyloctane.

[0026] As used herein, the term “mineral oil” refers to oil derived from refined petroleumbased hydrocarbons. It typically contains mineral oil saturated hydrocarbons (MOSH) such as paraffins and naphthenes, and mineral oil aromatic hydrocarbons (MOAH), such as alkylated mono- and poly-aromatic rings. Mineral oil is distinct from vegetable or animal derived oils, which have a biological origin.

[0027] As used herein, “triglycerides” are fatty acid esters of glycerol. As used herein, "medium chain triglycerides" or “MCTs” are fatty acid esters of glycerol with a chain length of 6 to 12 carbon atoms. As used herein, "long chain triglycerides" are fatty acid esters of glycerol with a chain length of 14 to 18 carbon atoms.

[0028] As used herein, the term “nanoemulsion” refers to an emulsion in which organic phase droplets dispersed in a continuous aqueous phase have a dso in the nanometer range.

[0029] As used herein, the droplet diameter “d”, or “D”, refers to the equivalent spherical diameter (esd), i.e. , the diameter of a sphere having the same volume as a given droplet. The term “dn”, or “Dn” refers to the diameter below which n% by volume of the droplet population is found. Thus, the term “dso”, or “Dso” refers to the volume-based median droplet diameter below which 50% by volume of the droplet population is found.

[0030] As used herein, the terms “patient,” “subject,” “individual,” and the like, as used herein, are interchangeable and refer to any animal, which may be a human or a nonhuman animal. Compositions of the invention are particularly suited to use in humans and so the patient is preferably a human.

[0031] As used herein, the terms “prevention” of or “preventing” a disorder, disease, or condition refers to reducing the seventy and / or reducing the occurrence of the disorder, disease, or condition in a treated sample relative to an untreated control sample, and includes delaying onset and / or progression of the disorder or condition relative to the untreated control sample.

[0032] As used herein, the term “soybean-based phospholipids” refers to a mixture of naturally occurring phospholipids derived from soybeans. Soybean-based phospholipids may be extracted during the soybean oil refining process. The major phospholipid components of soybean-based phospholipids include phosphatidylcholine, phosphatidylethanolamine and phosphatidylinositol.

[0033] As used herein, the term “ocular disorder” refers to any of the signs, symptoms, and / or underlying cause(s) of any physiological disorder that affects the eye or vision.

[0034] As used herein, the term “treat,” “treating,” or “treatment,” when used in connection with a disorder or condition, includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the disorder or condition. Improvements in or lessening the seventy of any symptom of the disorder or condition can be readily assessed according to standard methods and techniques known in the art.

[0035] As will be understood by one of ordinary skill in the art, each range disclosed herein includes all possible subranges as well as individual numerical values within that range, including endpoints. As a non-limiting example, a range of “0.001% to 0.02%” includes the end-points of 0.001% and 0.02%, and would be understood to specifically disclose subranges such as “0.004% to 0.01%,” “0.005% to 0.02%,” etc., as well as all individual numbers within the disclosed range, for example, 0.001%, 0.004%, 0.005%, 0.01%, 0.02%, etc.Detailed description

[0036] The present inventors have surprisingly discovered that stable ophthalmic compositions may be provided in the form of emulsions containing an organic phase comprising at least one semifluorinated alkane, and an aqueous phase. The emulsionsare for ocular applications, i.e. , they are suitable for application to the human eye for the treatment of an ocular disorder such as dry eye disease, preferably without causing serious irritation or other adverse effects.

[0037] From a clinical perspective, it is highly beneficial to be able to provide a stable ophthalmic composition that contains both a semifluorinated alkane and an aqueous phase. Without wishing to be bound by theory, it is believed that the semifluorinated alkane provides its own ocular disorder treatment and / or prevention effect on evaporative DED (thus intersecting the disease cycle with effects on both inflammation and tear evaporation), whilst the aqueous phase provides inter alia good wetting properties suitable for treating aqueous-deficient DED. The compositions may therefore be suitable for providing effective treatment of both aqueous-deficient DED and evaporative DED, meaning that patients with mixed-type DED may only need to apply one composition in order to treat both types of DED.

[0038] Emulsions for ocular applications which contain semifluorinated alkanes have not previously been described. The inventors’ finding of the disclosed stable ophthalmic emulsions is particularly surprising in view of the density difference between semifluorinated alkanes and water, which makes formulating stable emulsions challenging.

[0039] Formulating emulsions for ocular applications presents further challenges beyond the incompatibility of semifluorinated alkanes and water. For example, the eye is a particularly sensitive location for topical administration, so measures must be taken to minimize irritation to the eye and provide compositions which are acceptable for application to, and interaction with, the surface of the eye. This includes ensuring that the emulsions can be easily applied to the eye, and that the emulsions spread easily across the surface of the eye to avoid the need to rub the medicament into the eye, which is highly undesirable.

[0040] Providing an emulsion rather than an aqueous system as conventionally used for aqueous-deficient DED is also advantageous because aqueous solutions often produce itch, burn or other unpleasant side effects upon contact with the eye. It is believed that the emulsions of the present invention will not cause significant itching or burning sensations upon contact with the eye, especially compared to known aqueous ophthalmic solutions.

[0041] The emulsions of the invention are physically stable on visual inspection, meaning that the organic phase and the aqueous phase do not separate, and remain stable for extended period of time. Oil-in-water emulsions become unstable when organic phase droplets finely dispersed in an aqueous phase come into contact and aggregate. This process limits the stability of the emulsion during storage, and proceeds more slowly themore viscous the continuous phase of the emulsion is. However, surprisingly, the inventors have found that the organic phase droplets dispersed in the aqueous phase in the described emulsions do not coalesce.

[0042] Therefore, the described emulsions are stable, even at low viscosities. It is desirable for ophthalmic compositions that are intended to be provided as eye drops to have low viscosities because they spread readily on the surface of the eye, so require little or no mechanical assistance for distribution. A further advantage is that low viscosity compositions create only a slight foreign body sensation in the eye on application, so are more tolerable for the patient. In addition, lower viscosity compositions are easier to dispense from dosing containers, particularly eye drop dispensing containers.Emulsions of the invention

[0043] The invention provides an emulsion for ocular applications, comprising (a) an organic phase comprising at least one semifluorinated alkane; (b) an aqueous phase; and (c) a surfactant; wherein the emulsion comprises about 15% or less by weight of the organic phase.

[0044] Surprisingly, the inventors have found that emulsions for ocular applications can be provided with a relatively low amount of organic phase, and therefore a relatively low amount of semifluorinated alkane. This is advantageous because a relatively large aqueous phase allows for versatility in the amount of, and type of, aqueous-compatible components that can be included in the emulsion. These components include active pharmaceutical ingredients for treating ocular disorders, and other aqueous-compatible components that have beneficial effects on the eye, such as hyaluronic acid. Without wishing to be bound by theory, a relatively low amount of semifluorinated alkane is believed to provide benefits in treating DED because the semifluorinated alkane treats DED by forming a thin film on the eye to prevent evaporation of water. It is therefore advantageous for ocular applications to be able to form a stable emulsion of an aqueous phase and a semifluorinated alkane containing a low amount of semifluorinated alkane.

[0045] The emulsion may comprise about 10% or less by weight of the organic phase, for example about 0.05% to about 10% by weight, about 0.1 % to about 5% by weight, about 0.1 % to about 1 % by weight, about 0.1 % to about 0.8% by weight, or about 0.5% to about 0.8% by weight.

[0046] The emulsion will therefore typically be an oil-in-water emulsion i.e. the aqueous phase may form the outer phase of the emulsion, the organic phase may form the inner phase of the emulsion, and the organic phase may be dispersed as droplets in the aqueous phase.

[0047] The total amount of surfactant in the emulsion may be in the range of from about 0.01 % to about 5% by weight, for example from about 0.1 % to about 4% by weight, fromabout 0.1 to about 1 % by weight or from about 0.1 to about 0.8% by weight. It is beneficial to minimize the amount of surfactant in emulsions for ocular applications because conventional surfactants can cause irritation to the eye and a particular advantage of the emulsions of the present invention is the ability to form a stable emulsion containing a semifluorinated alkane and an aqueous phase which contains a very low amount of surfactant, such as about 1 % by weight or less.

[0048] The emulsion may comprise about 0.05% to about 5% by weight of the organic phase and the total amount of surfactant in the emulsion may be in the range of from about 0.1 % to about 4% by weight. The emulsion may comprise about 0.1 % to about 1 % by weight of the organic phase and the total amount of surfactant in the emulsion may be in the range of from about 0.1 % to about 0.8% by weight.

[0049] The emulsion may comprise an amount of surfactant of at least 30% by weight of the organic phase, preferably at least 40% by weight. The emulsion may comprise an amount of surfactant in the range of from about 30% to about 90% of the organic phase by weight, preferably from about 40% to about 80% by weight of the organic phase.

[0050] The surfactant is suitable for inclusion in an emulsion for ophthalmic applications, and is therefore an ophthalmically compatible surfactant. The surfactant may be selected from the group consisting of ethylene oxide-formaldehyde-p-octylphenol copolymer (e.g. Tyloxapol), poloxamers such as poloxamer 188, a polyethoxylated sorbitan fatty acid ester such as polysorbate 20 (e.g. Tween 20) or polysorbate 60 (e.g. Tween 60) or polysorbate 80 (e.g. Tween 80), polyethoxylated castor oil (e.g. Kolliphor EL, formerly known as Cremaphor EL), PEG-40-hydrogenated castor oil, PEG-40 stearate, PEG 400, polyoxyethylene (40) isooctyl phenyl ether (e.g. Octoxynol-40), sorbitan tristearate (e.g. Span 65), octylphenol ethoxylate (e.g. Triton X 405), phospholipids (e.g. Lipoid S75), a lecithin, a betaine, cationic surfactants such as cetalkonium chloride (also known as BDMHDA), and combinations thereof. Preferably, the surfactant may be selected from the group consisting of ethylene oxide-formaldehyde-p-octylphenol copolymer (e.g. Tyloxapol), poloxamers such as poloxamer 188, a polyethoxylated sorbitan fatty acid ester such as polysorbate 20 (e.g. Tween 20) or polysorbate 60 (e.g. Tween 60) or polysorbate 80 (e.g. Tween 80), polyethoxylated castor oil (e.g. Kolliphor EL), PEG-40-hydrogenated castor oil, PEG-40 stearate, PEG 400, polyoxyethylene (40) isooctyl phenyl ether (e.g. Octoxynol-40), sorbitan tristearate (e.g. Span 65), octylphenol ethoxylate (e.g. Triton X 405), phospholipids (e.g. Lipoid S75), cationic surfactants such as cetalkonium chloride, and combinations thereof. More preferably, the surfactant may be selected from the group consisting of ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamer 188 and phospholipids (e.g. Lipoid S75), or combinations thereof. Most preferably, the surfactant may be selected from ethylene oxide-formaldehyde-p-octylphenol copolymer, phospholipids (e.g. Lipoid S75), or combinations thereof.

[0051] In a preferred embodiment, the surfactant comprises phospholipids. A preferred phospholipid comprises soybean-based phospholipids, preferably soybean-based phospholipids comprising about 30% to about 95% phosphatidylcholine based on the total weight of the phospholipids, preferably about 60% to about 80% phosphatidylcholine, and most preferably about 70% to about 80% phosphatidylcholine, such as about 70% phosphatidylcholine.

[0052] The emulsion may comprise a main surfactant and one or more co-surfactants. For example, the emulsion may comprise (i) a main surfactant in the range of from about 1 % to about 3% by weight of the emulsion and (ii) one or more co-surfactants in the range of from about 0.0001 % to about 2% of the emulsion, for example 0.001 % to about 1 % of the emulsion. The surfactant may comprise phospholipids and one or more cosurfactants.

[0053] The emulsion may be a nanoemulsion. Nanoemulsions are particularly stable because the organic phase droplets have a reduced propensity to aggregate. The droplet diameter of the inner organic phase droplets, dso, may be in the range of from about 50 to about 500 nm, from about 100 to about 300 nm or from about 100 to about 220 nm. Nanoemulsions with a dso size of less than about 220 nm are advantageous because they can be subjected to filter sterilization.

[0054] The invention also provides an emulsion for ocular applications, comprising (a) an organic phase comprising at least one semifluorinated alkane; (b) an aqueous phase; and (c) phospholipids; wherein the emulsion comprises about 15% or less by weight of the organic phase. Said emulsion may be used in a method of treatment of an ocular disorder, preferably DED.

[0055] The emulsion may not comprise an active pharmaceutical ingredient (other than the semifluorinated alkane). For example, the emulsion may not comprise propofol. Aqueous phase

[0056] The aqueous phase may comprise hyaluronic acid and / or hyaluronate.

[0057] Hyaluronic acid is a naturally occurring highly viscous glycosaminoglycan consisting of glucose derivatives D-glucuronic acid and N-acetyl-D-glucosamine. Depending on the extraction method, the molecular weight Mw of the hyaluronic acid may be in the range of 50,000 to 10,000,000 g / mol. Hyaluronic acid is a component of the extracellular matrix of vertebrates and, in particular, a natural component of human eye fluids. The hyaluronic acid may be obtained from animal or vegetable sources or may be produced synthetically or semi-synthetically.

[0058] The hyaluronate may be selected from the group consisting of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, and mixtures thereof. Preferably, the hyaluronate is sodium hyaluronate.

[0059] The hyaluronic acid and / or hyaluronate may have a molecular weight Mw of 50,000 to 10,000,000 g / mol, or 100,000 to 5,000,000 g / mol, preferably 250,000 to 1,000,000 g / mol.

[0060] The emulsion may comprise hyaluronic acid and / or hyaluronate in an amount of at least about 0.01 % by weight, for example at least 0.15% by weight, or at least 0.2% by weight. The emulsion may comprise hyaluronic acid and / or hyaluronate, preferably sodium hyaluronate, in an amount of about 0.1% to about 5% by weight, for example about 0.1% to about 2% by weight, or about 0.15% to about 0.35% by weight.

[0061] The aqueous phase of the emulsion may comprise an active pharmaceutical ingredient for the treatment of an ocular disorder, such as dry eye disease.Organic phase

[0062] The organic phase of the disclosed emulsions comprises at least one semifluorinated alkane. The organic phase may comprise at least 90% by weight semifluorinated alkane, for example the organic phase may consist essentially of semifluorinated alkane.

[0063] The at least one semifluorinated alkane may comprise F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may comprise F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, F6H10 or any combination thereof. The at least one semifluorinated alkane may comprise F4H5, F6H8, or a combination thereof. The at least one semifluorinated alkane may comprise F4H5 and the organic phase may be substantially free of other semifluorinated alkanes. Preferably, the at least one semifluorinated alkane comprises F6H8 and, more preferably, the organic phase may be substantially free of other semifluorinated alkanes. As used herein, a composition may be “substantially free of other semifluorinated alkanes” when the other semifluorinated alkanes are present at a relative amount of 2% (w / w) or less, preferably 1% (w / w) or less, or more preferably 0.5% (w / w) or less based on the total amount of semifluorinated alkanes in the composition.

[0064] The organic phase may comprise at least 90% by weight F6H8, and may for example consist essentially of F6H8. F6H8 may be the only semifluorinated alkane in the organic phase of the emulsion.

[0065] In addition to the at least one semifluorinated alkane, the organic phase may comprise at least one other ophthalmically acceptable oil, preferably wherein the at least one ophthalmically acceptable oil is selected from triglycerides and mineral oil. The organic phase may consist essentially of at least one semifluorinated alkane, preferably F6H8, and at least one ophthalmically acceptable oil selected from triglycerides and mineral oil.

[0066] Triglycerides may include medium chain triglycerides and long chain triglycerides. Preferably, the ophthalmically acceptable oil is a medium chain triglyceride. Medium chain triglycerides can advantageously prevent evaporation of the aqueous component of the emulsion, thereby preventing or reducing drying of the tear film or emulsion after application to the eye.

[0067] Suitable triglycerides are available in the form of synthetic, semisynthetic or natural oils, such as olive oil, palm oil, almond oil, coconut oil or mixtures thereof. Preferred triglycerides are obtainable from coconut oil. Such medium chain triglycerides are prepared, for example, from the oil of the endosperm of Cocos nucifera L. (the solid dried part), or E / asesis guineensis Jacq. Medium chain triglycerides that may be used include neutral oils, for example those obtainable under the trade names Myritol®312, Myritol®318, or Myritol®331 , commercially available from Cognis Ltd., Japan. Medium chain triglycerides of the type described in the European Pharmacopoeia, European Pharmacopoeia 5.0, 01 / 2010:0868, page 3471, Triglyceridea satnata media may also be used.

[0068] The medium chain triglyceride may be formed from at least 80 wt%, preferably at least 90 wt%, and more preferably at least 95 wt%, C8-C12-fatty acids, preferably C8-C10-fatty acids, based on the total weight of the fatty acids in the medium chain triglyceride. The medium chain triglyceride may be a saturated medium chain triglyceride. The saturated medium chain triglyceride may be formed from at least 80 wt%, preferably at least 90 wt%, and more preferably at least 95 wt%, saturated C8- and C10-fatty acids based on the total weight of the fatty acids in the medium chain triglyceride.

[0069] Other suitable medium chain triglycerides are commercially available under the trade names Acomed®, Captex®, Neobee®M5F, Miglyol®810, Miglyol®812, Mazole®, or Sefsol®860.

[0070] Particularly preferred medium chain triglycerides are caprylic-capric acid triglycerides, i.e. a mixture formed from esterified saturated C8- and C10-fatty acids. This mixture has the advantage that the saturated fatty acids provide improved stability of the lipid film and thus a surprisingly improved longer dwell time of the composition in the eye. One example of such a preferred medium chain triglyceride is Myritol®318.

[0071] The at least one ophthalmically acceptable oil and the at least one semifluorinated alkane may be present in the organic phase at a weight ratio of about 1:1 to about 4:1, preferably about 3:1.

[0072] Similarly, the organic phase may comprise, by weight: about 20 to about 30% semifluorinated alkane and about 70 to about 80% ophthalmically acceptable oil. The organic phase may consist of, by weight: about 20 to about 30% semifluorinated alkaneand about 70 to about 80% ophthalmically acceptable oil, preferably about 25% semifluorinated alkane and about 75% ophthalmically acceptable oil.

[0073] When the organic phase contains a mixture of at least one semifluorinated alkane and at least one ophthalmically acceptable oil, the organic phase may have a density of about 1.0 to about 1.1 g / cm3This may be achieved by using the ratios of semifluorinated alkane and ophthalmically acceptable oil described above. As described above, semifluorinated alkanes have a higher density than water (for example, F6H8 has a density of 1.334 g / cm3). Ophthalmically acceptable oils have lower densities than water. For example, the ophthalmically acceptable oil used in the examples below is an MCT with a density of 0.95 g / cm3. The density of an organic phase containing a mixture of semifluorinated alkane and ophthalmically acceptable oil is therefore closer to that of water than the density of an organic phase containing semifluorinated alkanes alone. Without wishing to be bound by theory, it is believed that a smaller density difference between the inner organic dispersed phase and the continuous outer aqueous phase improves the stability of the emulsion because the cream ing / sedimentation velocity of the dispersed droplets is lowered.

[0074] Providing an organic phase with a density of about 1.0 to about 1.1 g / cm3may therefore provide additional stability advantages for the emulsion. As shown in the examples, emulsions in which the organic phase contains semifluorinated alkane alone are surprisingly stable. However, even better stability is unexpectedly achieved using a blend of semifluorinated alkane and ophthalmically acceptable oil as the organic phase to achieve an organic phase density of about 1.0 to about 1.1 g / cm3(see Figure 2).

[0075] The organic phase may consist essentially of (i) F6H8, or (ii) a mixture of F6H8 and an ophthalmically acceptable oil such that the density is about 1.0 to about 1.1 g / cm3.Further general features of the surfactant-containing emulsions

[0076] The emulsion may also comprise an osmoprotectant. The emulsion may comprise from about 0.5% to about 7% osmoprotectant by weight of the emulsion. The osmoprotectant may comprise dextrose, glycerin, propylene glycol, sorbitol, mannitol, urea, polyethylene glycol, boric acid, magnesium sulfate, zinc sulfate, sodium chloride, potassium chloride, calcium chloride, sodium sulfate, sodium hydrogen phosphate, trisodium citrate, trisodium phosphate, and mixtures thereof. Preferably, the osmoprotectant is glycerin. The emulsion may comprise from about 0.5% to about 5% by weight of glycerin, preferably from about 0.5% to about 3.5% by weight. The emulsion may have an osmolality of about 250 to about 350 mOsm / kg.

[0077] The emulsion may comprise about 5% or less by weight of the organic phase, and the Dso of the inner organic phase droplets may be 20 pm or less. The emulsion maycomprise about 10% by weight of the organic phase, and the Dso of the inner organic phase droplets may be about 110 pm or less.

[0078] The emulsion may have a viscosity of less than 5000 mPa s at 20°C, less than 350 mPa s at 20° C, less than 250 mPa s at 20° C, less than 200 mPa s at 20° C, less than 150 mPa s at 20° C, or less than 100 mPa s at 20° C. The viscosity is typically measured at 19.2 rpm. It is advantageous for the emulsion to have low viscosities within these ranges, for ease of application to the eye when applied as eye drops, as described above.

[0079] The emulsion may have a negative Zeta potential, which is indicative of a stable emulsion. The emulsion may have a Zeta potential in the range of from about -0.5 mV to around -80 mV, for example from about -0.5 mV to about -15 mV.

[0080] The emulsion may comprise sodium hydroxide, and optionally also hydrochloric acid, for pH adjustment.

[0081] The pH of the emulsion is typically between about 6 and about 9. The emulsion may comprise a buffer system to maintain the pH of the emulsion between 6 and 9. Typically, the buffer system may be a phosphate or citrate buffer.

[0082] In some instances, the emulsion may not include polyquaternium-1.Preferred emulsion compositions

[0083] The emulsion may comprise from about 0.1 % to about 4% by weight of surfactant, and from about 0.5% to about 5% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 3.5% by weight of osmoprotectant, preferably glycerin.

[0084] The emulsion may comprise from about 0.1 % to about 4% by weight of poloxamer, for example poloxamer 188, and from about 0.5% to about 5% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 3.5% by weight of osmoprotectant, preferably glycerin.

[0085] The emulsion may comprise from about 0.1% to about 4% by weight of ethylene oxide-formaldehyde-p-octylphenol copolymer, and from about 0.5% to about 5% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 3.5% by weight of osmoprotectant, preferably glycerin.

[0086] The emulsion may comprise from about 0.1% to about 4% by weight of phospholipids, and from about 0.5% to about 5% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 3.5% by weight of osmoprotectant, preferably glycerin.Methods of treating ocular disorders

[0087] The invention also provides a method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of an emulsion disclosed herein.

[0088] The invention also provides an emulsion disclosed herein for use in a method for the treatment or temporary prevention of at least one ocular disorder, the method comprising administering to a patient in need thereof an effective amount of the emulsion.

[0089] The invention also provides the use of an emulsion disclosed herein in the manufacture of a medicament for use in a method for the treatment or temporary prevention of at least one ocular disorder, the method comprising administering to a patient in need thereof an effective amount of the emulsion.

[0090] Any of the emulsions described above may be used in the methods of thetreatment or temporary prevention of at least one ocular disorder described herein.

[0091] The at least one ocular disorder may be dry eye disease. The dry eye disease may be evaporative dry eye disease, aqueous deficient dry eye disease, or both. As explained above, the emulsions of the invention are particularly beneficial for treating mixed-type DED, where the patient has both evaporative DED and aqueous deficient DED.

[0092] The emulsion may be topically administered to the ocular surface of the patient, or topically administered to the cornea of the patient, or instilled into the conjunctival sac of the patient. The ophthalmic composition is preferably administered in the form of eye drops.

[0093] After application of eye drops, it can be useful to use nasolacrimal compression, obstruction, or occlusion (for example by applying compression to the lacrimal sac at the medial canthus). This procedure can reduce the amount of liquid entering the nasolacrimal duct and draining into the throat where they can lead to sensations of bad taste.

[0094] Proper dosages of the ophthalmic emulsions of the present disclosure are concentration-dependent. To determine the specific dose, a skilled artisan would have to take into account kinetics and absorption characteristics of the particular ingredients. In addition, the dosage may be dependent on the route of administration. The dosages may also be dependent on the degree of antibacterial and / or anti-inflammatory effect desired in a patient.

[0095] Methods of treating comprise administration of a daily dose of an ophthalmic emulsion of the present disclosure to a subject in need thereof. Determining and adjusting an appropriate dosing regimen (e.g., adjusting the number of doses and frequency of dosing) per day can be performed by one of ordinary skill in the relevant art, and willdepend upon various factors such as the nature and progression of a disorder and / or condition associated with allergies and eye redness, the health, and / or age of the subject. The ophthalmic emulsions of the present disclosure may be administered to a patient in a single dose per day, in two doses per day, in three doses per day, in four doses per day, etc. up to, for example, ten doses per day. The composition may be administered to a patient for at least one week, at least two weeks, at least three weeks, at least one month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 12 months, at least one year, or for more than one year.

[0096] When using eye drops, one dose is typically a single droplet per eye. The emulsions disclosed herein may be used in a method of treatment of an ocular disorder, preferably DED, wherein the method comprises administering one drop to each eye of the patient once daily, twice daily, three times daily or four times daily. Twice daily dosing may be particularly appropriate for emulsions of the invention, especially when used to treat DED.Container closure systems

[0097] The invention also provides a container closure system for dispensing an ophthalmic composition containing an emulsion disclosed herein, preferably wherein the container closure system is adapted to dispense the emulsion in the form of eye drops. Any of the emulsions described above may be included in the container closure systems disclosed herein.

[0098] The container closure system may comprise a) a bottle or vial and b) a dropper outlet for application of the emulsion to the eye. Such container closure systems are advantageous because they allow direct application of emulsions to the eye as eye drops, to treat ocular disorders, in particular DED.

[0099] The bottle or vial may be a multi-dose bottle or multi-dose vial. The multi-dose bottle or multi-dose vial may contain from about 4 to about 150 drops of the emulsion, for example from about 10 to about 60 drops of the emulsion.

[0100] The bottle or vial may contain from about 0.05 mL to about 3 mL of the emulsion, for example from about 0.1 mL to about 1 mL of the emulsion or from about 0.2 mL to about 0.6 mL of the emulsion.Methods of manufacture

[0101] The invention also provides a process for preparing an emulsion disclosed herein, comprising mixing the organic phase with the aqueous phase and emulsifying the organic phase and aqueous phase using high shear homogenization, preferably at between about 1,000 rpm and about 20,000 rpm. The high shear homogenization may be followed by high pressure homogenization, preferably wherein the high pressure homogenization takes place at a pressure of between about 100 bar and 2,000 bar.BRIEF DESCRIPTION OF THE DRAWINGS

[0102] Figure 1 shows macroscopic images of emulsions of the invention.

[0103] Figure 2 shows accelerated stability testing of a marketed composition comprising 0.2 wt% MCT as the oil phase, and an emulsion comprising a blend of MCT and F6H8 as the oil phase.Experimental methodsOsmolalityThe osmolality of the prepared ophthalmic compositions can be measured at a temperature of 20°C with a micro-osmometer (Hermann Robling Messtech nik, Germany).Viscosity

[0104] The viscosity of the prepared ophthalmic compositions can be measured at 19.2 rpm and 20°C, preferably by the cone-plate method, using for example a Wells Brookfield cone-plate viscometer of the type DV-III+ (Brookfield Engineering Laboratories Vertribut GmbH, Germany) with a CP51 spindle.Measurement of organic phase droplet size

[0105] The volume-based median droplet diameter, dso, of the dispersed organic phase can be measured by dynamic light scattering (DLS) at 25 °C, using a particle size analyser (e.g. Malvern Zetasizer Pro Red, Malvern Instruments, Malvern, UK). The median droplet size on a volume basis, dso, can be determined from the particle size distribution output obtained from DLS. For example, each sample may be added into a 12mm square disposable polystyrene cuvette and fixed in the direction of laser light beam. The signal of the scattered light can be measured, and the droplet sizes were determined based on the physical properties of the scattered light. The integrated software, for example from Malvern, can then be used to evaluate the results.

[0106] Droplet diameters, D, can be determined by laser diffraction, for example in accordance with Ph. Eur. 2.9.31. The Dso droplet diameter (i.e. the volume-based median droplet diameter) of the dispersed organic phase may be determined using routine laser diffraction methods. In particular, Dso may be determined using a light diffraction particle analyser (e.g., Malvern Mastersizer 2000) preferably equipped with a circulation system, for example using Mie theory. Preferably, a dispersant is used. Example measurement conditions include the use of water as a dispersant, with an agitation of 400 rpm.Zeta potential

[0107] Zeta potential can be determined by dynamic light scattering (DLS) at 25 °C, using a particle size analyser (e.g. Malvern Zetasizer Pro Red, Malvern Instruments, Malvern, UK). For example, Zeta potential can be measured using Folded Capillary ZetaCells and undiluted samples at 25 °C. The integrated software, for example from Malvern, can be used to evaluate the results.Molecular weight, Mw

[0108] Mw can be determined by size exclusion chromatography, specifically gel permeation chromatography (GPC), with a monodisperse polystyrene equivalent molecular weight calibration standard and GPC columns (manufactured by PSS, applied column combination: SDV 5pm 1000A, SDV 5pm 500A, SDV 5pm 100A). The flow rate in the columns may be 1.0 ml / min, eluent: tetrahydrofuran, column temperature: 40°C, a differential refractive index detector (Rl) and a UV-detector (254nm) may be used. Unless otherwise stated, the molecular weight is the number average molecular weight.EXAMPLES

[0109] The following emulsions were prepared using first a step of high shear homogenization (between 1000-20000 rpm) and second step of high-pressure homogenization (at 100-2000 bar pressure, 1-10 passes).

[0110] The F6H8 used in the following examples consisted essentially of 1 -perfluorohexyloctane and less than 0.5% (w / w) of 2-perfluorohexyloctane.

[0111] In the tables below, the phospholipids used were soybean-based phospholipids (Lipoid S75).

[0112] The exemplified emulsions are intended to be administered as eye drops for use in DED therapy.Table 1: Composition 1: Phospholipid-based emulsion comprising 0.5% organic phase Component Concentration Amount (kg, 100(mg / mL) kg batch size)Glycerine (85%) 12.000 1.200Phospholipids 3.000 0.300Organic Phase (100% 5.000 0.500F6H8)NaOH / HCI q,s. for pH 6-9 q.s. for pH 6-9Water for injection (WFI) ad 1mL ad 100 kgTable 2: Composition 2: Phospholipid-based emulsion comprising 5.0% organic phase Component Concentration Amount (kg, 100(mg / mL) kg batch size)Glycerine (85%) 12.000 1.200Phospholipids 30.000 3.000Organic Phase (100% 50.000 5.000F6H8)NaOH / HCI q,s. for pH 6-9 q.s. for pH 6-9Water for injection (WFI) ad 1mL ad 100 kgTable 3: Composition 3: Nanoemulsion with Tyloxapol and 0.5% organic phase Component Concentration Amount (kg, 100(mg / mL) kg batch size)Glycerine (85%) 12.000 1.200Tyloxapol 4.000 0.400Organic Phase (100% 5.000 0.5000F6H8)NaOH / HCI q,s. for pH 6-9 q.s. for pH 6-9Water for injection (WFI) ad 1mL ad 100 kgTable 4: Composition 4: Nanoemulsion with Tyloxapol and 5.0% organic phase Component Concentration Amount (kg, 100(mg / mL) kg batch size)Glycerine (85%) 12.000 1.200Tyloxapol 35.000 3.500Organic Phase (100% 50.000 5.000F6H8)NaOH / HCI q,s. for pH 6-9 q.s. for pH 6-9Water for injection (WFI) ad 1mL ad 100 kgTable 5: Composition 5: Nanoemulsion with Poloxamer 188 and 0.5% organic phase Component Concentration Amount (kg, 100(mg / mL) kg batch size)Glycerine (85%) 12.000 1.200Poloxamer 188 2.000 0.200Organic Phase (100% 5.000 0.500F6H8)NaOH / HCI q,s. for pH 6-9 q.s. for pH 6-9Water for injection (WFI) ad 1mL ad 100 kgTable 6: Composition 6: Nanoemulsion with Poloxamer 188 and 5.0% organic phase Component Concentration Amount (kg, 100(mg / mL) kg batch size)Glycerine (85%) 12.000 1.200Poloxamer 188 20.000 2.000Organic Phase (100% 50.000 5.000F6H8)NaOH / HCI q,s. for pH 6-9 q.s. for pH 6-9Water for injection (WFI) ad 1mL ad 100 kg

[0113] Due to the presence of surfactants and the use of a high-pressure homogenization step, all the above emulsions resulted in dispersed organic phase droplets with sizes in the nanometer range (i.e., nanoemulsions). Table 7 provides an overview of the median droplet size (dso) and the Zeta potential measured by dynamic light scattering (DLS). All tested emulsions had a negative Zeta potential, indicating formation of a physically stable emulsion.Table 7: Organic phase droplet size characterization of emulsions containing surfactants Composition dso (nm, ±SD) Zeta potential (mV)Composition 1 (Table 1) 205 -9.2Composition 2 (Table 2) 208 -11.6Composition 3 (Table 3) 158 -12.5Composition 5 (Table 5) 151 -1.6Composition 6 (Table 6) 166 -1.4

[0114] The macroscopic appearance of nanoemulsions 1 , 5 and 6, which have different concentrations of internal / dispersed organic phase, can be seen in Figures 1 (a), (b) and (c) respectively.Stability testing

[0115] As described above, the inventors have surprisingly found that using appropriate organic component blends can result in a density of the inner organic phase closer to that of water, which can support the stability of the emulsion. In this way, the inventors have found that mixtures of F6H8 or other semifluorinated alkanes with ophthalmically acceptable oils have additional benefits in terms of physical stability. Oils such as MCT and mineral oil have a much lower density than of pure F6H8. For example, F6H8 has a density of 1.334 g / cm3, and the MCT Myritol®318 has a density of 0.95 g / cm3.

[0116] Stability testing was performed to compare the accelerated stability of two emulsions: (i) a marketed formulation with 0.2 wt% organic phase comprising only MCT (Table 8 below) and (i) an emulsion with 0.2 wt% organic phase comprising a blend of F6H8 and MCT to result in a density of 1 (Table 9 below).Table 8: Marketed emulsion, with 0.2 wt% organic phase comprising MCT only Component Concentration (wt%)Carbomer (Carbopol 980, polyacrylic 0.0625acid polymer)Sodium hyaluronate 0.2400Glycerin 85% 2.9000NaOH 0.0231MCT (Myritol 318) 0.2000Water for injection Ad. 100Table 9: Emulsion with 0.2 wt% organic phase comprising a blend of F6H8 and MCT (Myritol 318)Component Concentration Amount (kg, 100 (mg / mL) kg batch size) Hyaluronic acid 2.400 0.2400Organic Phase 2.000 0.2000(MCT / F6H8 in a weightratio of 3:1)Carbopol 980 NF 0.625 0.0625Glycerine (85%) 29.000 2.9000NaOH 5.400 0.5400Water for injection (WFI) ad 1mL ad 100 kg

[0117] The systems were tested by analyzing the light transmission of the samples during high-speed centrifugation (using a photo centrifuge analyser, LUMiFuge®) and the measured instability index of each system was compared. The instability index is based on the particle concentration change in the emulsions, which may occur e.g., during creaming or sedimentation. The closer the instability index to 1 , the higher the instability of the system. With an instability index of 1 , there is no particle concentration change due to accumulation or sedimentation.

[0118] As shown in Figure 2, the formulations where the inner organic phase was modified by blending F6H8 with MCT to reach a density of 1 (Table 9) showed much higher stability than systems where the inner organic phase contained only MCT (Table 8).Additional stability data with surfactants and co-surfactants

[0119] The following emulsions were prepared and characterized to further evaluate the effect of each surfactant with and without the presence of a co-surfactant. For all emulsions, the organic phase was 2% by weight of the emulsion and consisted of F6H8.Table 10: Composition overviewComposition F6H8 Surfactant (wt%) Co-surfactant (wt%)7 2% 2% Polysorbate 80 (nonionic) None8 2% 2% Tyloxapol (nonionic) None9 2% 2% Lipoid S75 (amphiphilic / Nonezwitterionic)10 2% 2% Cremophor / Kolliphor EL (nonionic) None11 2% 0.001% Cetalkonium 2% Polysorbate 80 (nonionic) chloride (BDMHDA) 12 2% 0.001% Cetalkonium 2% Tyloxapol (nonionic) chloride (BDMHDA) 13 2% 0.001% Cetalkonium 2% Cremophor / Kolliphor EL (nonionic) chloride (BDMHDA) 14 2% 2% Polysorbate 80 (nonionic) 0.1% Poloxamer 188 15 2% 2% Tyloxapol (nonionic) 0.1% Poloxamer 188 16 2% 2% Lipoid S75 (amphiphilic / 0.1% Poloxamer 188 zwitterionic)17 2% 2% Cremophor / Kolliphor EL (nonionic) 0.1% Poloxamer 188 18 2% 2% Polysorbate 80 (nonionic) 1% PEG 40019 2% 2% Tyloxapol (nonionic) 1% PEG 40020 2% 2% Lipoid S75 (amphiphilic / 1% PEG 400zwitterionic)21 2% 2% Cremophor / Kolliphor EL (nonionic) 1% PEG 400

[0120] An aqueous solution of the surfactant (with or without co-surfactant) was prepared at pH 7.2 with 25 mM phosphate buffer. F6H8 was added to this solution followed by mixing using a high-shear mixer operating at 8600 rpm for 2 minutes. Nanoemulsions were obtained by processing the macroemulsions through three high-pressure homogenization cycles at 700 bar (GEA Panda Plus 2000 high-pressure homogenizer).

[0121] Droplet size and PDI (polydispersity index) were measured using the Zetasizer Pro (Malvern Panalytical, UK) at the day of manufacturing (to) and after 1, 2, 6, and 12 weeks of storage at ambient temperature (ti , t?, ts, t4, respectively). Measurements were conducted in triplicate for each batch, and no dilution was applied to avoid dilution-induced alterations in droplet size. Prior to each measurement, the emulsion was gentlyshaken. Zeta potential measurements were carried out immediately after production (t0) and after six weeks of storage at ambient temperature (t3).

[0122] The following tables show the results obtained from the formulations comprising Polysorbate 80 (Table 11), Tyloxapol (Table 12), Kolliphor EL (Table 13), and Lipoid S75 (Table 14) as the main surfactant, without and with co-surfactants.Table 11: Nanoemulsions with Polysorbate 80 as the main surfactant, without and with Cetalkonium chloride (BDMHDA), Poloxamer 188, or PEG 400 as co-surfactants Droplet size (nm, ±SD)Time No surfactant 0.001% BDMHDA 0.1% Poloxamer 188 1% PEG 400 to 87,92 ± 4,47 111,4 ± 1,69 91 ,35 ± 4,34 89,99 ± 7,09 ti 150,3 ± 1,57 152,8 ± 2,55 157,1 ± 1,97 155,4 ± 4,43 t2 176,1 ± 2,2 173,5 ± 5,21 175 ± 3,49 183 ± 3,52 t3 205,1 ± 4,86 202 ± 2,11 210 ± 5,38 218,2 ± 7,53 t4 250,9 ± 35,3 222,5 ± 2,16 246,2 ± 18,23 240,6 ± 6,05Zeta potential (mV, ±SD)TimeNo surfactant 0.001% BDMHDA 0.1% Poloxamer 188 1% PEG 400 to -12 ± 0,29 -0,1272 ± 0,37 0,4746 ± 0,37 0,8108 ± 0,44 t3 -14,11 ± 0,33 0,7148 ± 0,3 - 0,082 ± 0,31 -1 ,115 ± 1,06Table 12: Nanoemulsions with Tyloxapol as the main surfactant, without and with Cetalkonium chloride (BDMHDA), Poloxamer 188, or PEG 400 as co-surfactants Droplet size (nm, ±SD)Time No surfactant 0.001% BDMHDA 0.1% Poloxamer 188 1% PEG 400 to 84,85 ± 5,708 101,2 ± 4,162 113 ± 43,44 102 ± 3,23 ti 169,8 ± 2,216 174,4 ± 3,536 177,1 ± 2,858 102 ± 4,728 t2 192,4 ± 3,238 240,8 ± 57,85 201,2 ± 3,402 201,9 ± 1,384 t3 237,5 ± 3,654 239,1 ± 4,592 271,4 ± 4,927 254,2 ± 9,895 t4 294,1 ± 9,497 299,2 ± 7,576 307,1 ± 18,46 302 ± 29,33Zeta potential (mV, ±SD)TimeNo surfactant 0.001% BDMHDA 0.1% Poloxamer 188 1% PEG 400 to -1 ,007± 0,66 2,463 ± 0,72 -1,626 ± 3,26 -0,25 ± 0,72 t3 1,731 ± 1,84 1,25 ± 2,76 1,718 ±0,99 -2,372 ± 2,98Table 13: Nanoemulsions with Kolliphor EL as the main surfactant, without and with Cetalkonium chloride (BDMHDA), Poloxamer 188, or PEG 400 as co-surfactants Droplet size (nm, ±SD)Time No surfactant 0.001% BDMHDA 0.1% Poloxamer 188 1% PEG 400 to 107,2 ± 8,152 90,31 ± 5,119 97,26 ± 4,164 97,11 ± 6,309 ti 153,9 ± 2,486 152,8 ± 2,871 159,9 ± 3,201 166 ± 3,078 t2 171 ,6 ± 2,651 175 ± 2,172 183,4 ± 2,385 189,9 ± 4,398 t3 199,8 ± 3,693 203,7 ± 26,31 223,4 ± 7,752 222,9 ± 6,048 t4 245,5 ± 21 ,13 264 ± 62,67 247,2 ± 11 ,94 244,8 ± 6,237Zeta potential (mV, ±SD)TimeNo surfactant 0.001% BDMHDA 0.1% Poloxamer 188 1% PEG 400 to 1 ,834 ± 0,28 1 ,557 ± 0,15 0,4254 ± 3,17 1 ,034 ± 1 ,103 t3 0,03 ± 0,32 1 ,708 ± 0,28 0,6216 ± 0,23 -4,946 ± 2,79Table 14: Nanoemulsions with Lipoid S75 as the main surfactant, without and with Poloxamer 188, or PEG 400 as co-surfactantsDroplet size (nm, ±SD)TimeNo surfactant 0.1% Poloxamer 188 1% PEG 400to 87,56 ± 21 ,66 80,91 ± 3,858 85,19 ± 5,659ti 83,37 ± 20,56 97,22 ± 6,514 86,8 ± 17,28t2 81 ,78 ± 17,83 89,14 ± 24,55 99,67 ± 21 ,25t3 84,7 ± 23,75 168,8 ± 27,09 88,96 ± 13,05t4 79,13 ± 25,23 109,4 ± 18,57 92,73 ± 18,79Zeta potential (mV, ±SD)TimeNo surfactant 0.1% Poloxamer 188 1% PEG 400to -12,37 ± 1 ,1 -10,18 ± 1 ,05 -13,64 ± 0,20t3 -7,117 ± 1 ,3 -12,03 ± 2,647 -7,84 ± 0,74

[0123] The data shows that all compositions resulted in nanoemulsions with a relative stability since even after 3 months at ambient conditions, the droplet size of the innerorganic phase (F6H8) remains much below 500 nm and, in fact, for most cases below 300 nm. Although the tendency is for the droplet size to increase with time, the emulsions show relative stability despite the Zeta potential having values close to zero in most cases. Surprisingly, the emulsions comprising Lipoid S75 (phospholipids) showed remarkable stability and higher values of Zeta potential (Table 14). Although the standard deviation of the droplet size is higher than that of the other emulsions, the average droplet size remained below 100 nm. Interestingly, for all emulsions, the addition of a cosurfactant appears to provide no additional benefit in terms of droplet size and I or Zeta potential. Overall, it can be concluded that all compositions resulted in F6H8 nanoemulsions with relative stability, with the Lipoid S75 emulsion showing a superior behavior and exceptional stability.NUMBERED EMBODIMENTS

[0124] The invention provides the following numbered embodiments.

[0125] 1. An emulsion for ocular applications, comprising:an organic phase comprising at least one semifluorinated alkane;an aqueous phase; anda surfactant;wherein the emulsion comprises about 15% or less by weight of the organic phase.

[0126] 2. The emulsion of embodiment 1 , wherein the total amount of surfactant in the emulsion is in the range of about 0.01% to about 5% by weight, for example about 0.1% to about 4% by weight or about 0.1 to about 1 % by weight.

[0127] 3. The emulsion of embodiment 1 or embodiment 2, wherein the surfactant is selected from the group consisting of ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamers such as poloxamer 188, a polyethoxylated sorbitan fatty acid ester such as polysorbate 20 or polysorbate 60 or polysorbate 80, a polyethoxylated castor oil, PEG-40-hydrogenated castor oil, PEG-40 stearate, PEG 400, polyoxyethylene (40) isooctyl phenyl ether, sorbitan tristearate, octylphenol ethoxylate, phospholipids, a lecithin, a betaine, cationic surfactants such as cetalkonium chloride, and combinations thereof.

[0128] 4. The emulsion of any preceding embodiment, wherein the surfactant is selected from the group consisting of ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamer 188 and phospholipids, or combinations thereof.

[0129] 5. The emulsion of any preceding embodiment, wherein the surfactant consists of phospholipids.

[0130] 6. The emulsion of any one of embodiments 3-5, wherein the phospholipids comprise soybean-based phospholipids.

[0131] 7. The emulsion of embodiment 6, wherein the soybean-based phospholipids comprise about 30% to about 95% phosphatidylcholine based on the total weight of the phospholipids, optionally about 60% to about 80% phosphatidylcholine, such as about 70% to about 80% phosphatidylcholine, for example about 70% phosphatidylcholine.

[0132] 8. The emulsion of any one of embodiments 1-4 or 6-7, wherein the emulsion comprises a main surfactant and one or more co-surfactants.

[0133] 9. The emulsion of embodiment 8, wherein the emulsion comprises (i) a main surfactant in the range of from about 1 % to about 3% by weight of the emulsion and (ii) one or more co-surfactants in the range of from about 0.0001% to about 2% of the emulsion.

[0134] 10. The emulsion of any one of embodiments 1-4 or 6-9, wherein the surfactant comprises phospholipids and one or more co-surfactants.

[0135] 11. The emulsion of any preceding embodiment, wherein the emulsion is an oil in water emulsion.

[0136] 12. The emulsion of embodiment 11 , wherein the emulsion is a nanoemulsion, optionally wherein the size of the inner organic phase droplets, dso, is in the range of from about 50 to about 500 nm, for example from about 100 to about 300 nm.

[0137] 13. The emulsion of embodiment 11 , wherein the emulsion comprises about 5% or less by weight of the organic phase, and the Dso of the inner organic phase droplets is 20 pm or less.

[0138] 14. The emulsion of embodiment 11, wherein the emulsion comprises about 10% to about 15% by weight of the organic phase, and the Dso of the inner organic phase droplets is about 110 pm or less.

[0139] 15. The emulsion of any preceding embodiment, wherein the aqueous phase comprises hyaluronic acid and / or hyaluronate.

[0140] 16. The emulsion of embodiment 15, wherein the hyaluronate is selected from the group consisting of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, and mixtures thereof, optionally wherein the hyaluronate is sodium hyaluronate.

[0141] 17. The emulsion of embodiment 15 or embodiment 16, wherein the emulsion comprises hyaluronic acid and / or hyaluronate in an amount of at least about 0.01% by weight, for example about 0.1% to about 0.4%.

[0142] 18. The emulsion of any preceding embodiment, wherein the emulsion has a viscosity of <5000 mPa*s at 20°C, optionally less than 350 mPa s at 20°C.

[0143] 19. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane comprises F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof.

[0144] 20. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane comprises F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, F6H10 or any combination thereof; preferably F6H8, F6H10, or a combination thereof.

[0145] 21. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane is selected from F4H5, or F6H8, or a combination thereof.

[0146] 22. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane comprises F6H8, optionally wherein the organic phase is substantially free of other semifluorinated alkanes.

[0147] 23. The emulsion of any preceding embodiment, wherein F6H8 is the only semifluorinated alkane in the organic phase.

[0148] 24. The emulsion of any preceding embodiment, wherein F6H8 is the only semifluorinated alkane in the organic phase and the surfactant is soybean-based phospholipids comprising about 70% phosphatidylcholine based on the total weight of the phospholipids.

[0149] 25. The emulsion of any one of embodiments 1-21, wherein the at least one semifluorinated alkane comprises F4H5, optionally wherein the organic phase is substantially free of other semifluorinated alkanes.

[0150] 26. The emulsion of embodiment 25, wherein F4H5 is the only semifluorinated alkane in the organic phase.

[0151] 27. The emulsion of any preceding embodiment, wherein the emulsion comprises about 0.05% to about 10% by weight of the organic phase, for example about 0.1% to about 5% by weight of the organic phase, for example about 0.1% to about 1% by weight of the organic phase.

[0152] 28. The emulsion of any preceding embodiment, wherein the organic phase comprises at least 90% by weight semifluorinated alkane, for example wherein the organic phase consists essentially of semifluorinated alkane.

[0153] 29. The emulsion of embodiment 28, wherein the organic phase comprises at least 90% by weight F6H8, for example wherein the organic phase consists essentially of F6H8.

[0154] 30. The emulsion of any preceding embodiment, wherein the emulsion comprises an osmoprotectant, optionally wherein the osmoprotectant is selected fromdextrose, glycerin, propylene glycol, sorbitol, mannitol, urea, polyethylene glycol, boric acid, magnesium sulfate, zinc sulfate, sodium chloride, potassium chloride, calcium chloride, sodium sulfate, sodium hydrogen phosphate, trisodium citrate, trisodium phosphate, and mixtures thereof.

[0155] 31. The emulsion of embodiment 30, wherein the osmoprotectant is glycerin.

[0156] 32. The emulsion of embodiment 31, wherein the emulsion comprises from about 0.5% to about 5% by weight of glycerin, for example from about 0.5% to about 3.5% by weight of glycerin.

[0157] 33. The emulsion of any preceding embodiment, wherein the emulsion has an osmolality of from about 250 to about 350 mOsm / kg.

[0158] 34. The emulsion of any preceding embodiment, wherein the emulsion further comprises a buffer system, for example a phosphate or citrate buffer, to maintain the pH of the emulsion between 6 and 9.

[0159] 35. The emulsion of any preceding embodiment, wherein the aqueous phase of the emulsion comprises an active pharmaceutical ingredient for the treatment of an ocular disorder, such as dry eye disease.

[0160] 36. The emulsion of any one of embodiments 1-34, wherein the emulsion does not include an active pharmaceutical ingredient.

[0161] 37. The emulsion of any preceding embodiment, wherein the emulsion does not include propofol.

[0162] 38. The emulsion of any preceding embodiment, wherein the emulsion does not include polyquaternium-1.

[0163] 39. The emulsion of any one of embodiments 1-27 and 30-38 wherein the organic phase additionally comprises at least one ophthalmically acceptable oil, preferably wherein the ophthalmically acceptable oil is selected from triglycerides and mineral oil, for example a medium-chain triglyceride.

[0164] 40. The emulsion of embodiment 39, wherein the at least one ophthalmically acceptable oil and the at least one semifluorinated alkane are present in the organic phase at a weight ratio of about 1 : 1 to about 4: 1 , for example about 3: 1.

[0165] 41. The emulsion of embodiment 39 or embodiment 40, wherein the organic phase has a density of about 1.0 to about 1.1 g / cm3

[0166] 42. A method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of the emulsion of any preceding embodiment.

[0167] 43. The method of embodiment 42, wherein the at least one ocular disorder is dry eye disease, optionally evaporative dry eye disease, aqueous deficient dry eye disease, or both.

[0168] 44. The method according to embodiment 42 or 43, wherein the emulsion is topically administered to the ocular surface of the patient, or topically administered to the cornea of the patient, or instilled into the conjunctival sac of the patient.

[0169] 45. The method according to any one of embodiments 42-44, wherein the emulsion is administered in the form of eye drops.

[0170] 46. A container closure system for dispensing an ophthalmic composition containing the emulsion of any one of embodiments 1 -41.

[0171] 47. The container closure system of embodiment 46, wherein the container closure system comprises a) a bottle or vial and b) a dropper outlet for application of the emulsion to the eye.

[0172] 48. The container closure system of embodiment 47, wherein the bottle or vial is a multi-dose bottle or multi-dose vial.

[0173] 49. The container closure system of embodiment 48, wherein the bottle or vial contains from about 4 to about 150 drops of the emulsion, for example from about 10 to about 60 drops of the emulsion.

[0174] 50. The container closure system of any one of embodiments 46-49, wherein the bottle or vial contains from about 0.05 mL to about 3 mL of the emulsion, for example from about 0.1 mL to about 1 mL of the emulsion or from about 0.2 mL to about 0.6 mL of the emulsion.

[0175] 51. A process for preparing the emulsion of any one of embodiments 1-41, comprising mixing the organic phase with the aqueous phase and emulsifying the organic phase and aqueous phase using high shear homogenization, preferably at between about 1,000 rpm and about 20,000 rpm.

[0176] 52. The process of embodiment 51, where the high shear homogenization is followed by high pressure homogenization, preferably wherein the high pressure homogenization takes place at a pressure of between about 100 bar and 2,000 bar.

[0177] It will be understood that the inventors’ work has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

Claims

CLAIMS1. An emulsion for ocular applications, comprising:an organic phase comprising at least one semifluorinated alkane;an aqueous phase; anda surfactant;wherein the emulsion comprises about 15% or less by weight of the organic phase.

2. The emulsion of claim 1, wherein the total amount of surfactant in the emulsion is in the range of about 0.01% to about 5% by weight, for example about 0.1% to about 4% by weight or about 0.1 to about 1% by weight.

3. The emulsion of claim 1 or claim 2, wherein the surfactant is selected from the group consisting of ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamers such as poloxamer 188, a polyethoxylated sorbitan fatty acid ester such as polysorbate 20 or polysorbate 60 or polysorbate 80, PEG-40-hydrogenated castor oil, PEG-40 stearate, polyoxyethylene (40) isooctyl phenyl ether, sorbitan tristearate, octylphenol ethoxylate, phospholipids, a lecithin, a betaine, cationic surfactants such as cetalkonium chloride, and combinations thereof.

4. The emulsion of any preceding claim, wherein the surfactant is selected from the group consisting of ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamer 188 and phospholipids, and combinations thereof.

5. The emulsion of any preceding claim, wherein the surfactant comprises phospholipids and one or more co-surfactants.

6. The emulsion of any one of claims 1-4, wherein the surfactant consists of phospholipids.

7. The emulsion of any one of claims 3-6, wherein the phospholipids comprise soybeanbased phospholipids.

8. The emulsion of claim 7, wherein the soybean-based phospholipids comprise about 30% to about 95% phosphatidylcholine based on the total weight of the phospholipids,optionally about 60% to about 80% phosphatidylcholine, such as about 70% to about 80% phosphatidylcholine, for example about 70% phosphatidylcholine.

9. The emulsion of any preceding claim, wherein the emulsion is an oil in water emulsion, optionally wherein the emulsion is a nanoemulsion, optionally wherein the dso is in the range of from about 50 to about 500 nm, for example from about 100 to about 300 nm.

10. The emulsion of any preceding claim, wherein the aqueous phase comprises hyaluronic acid and / or hyaluronate, optionally wherein the hyaluronate is selected from the group consisting of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, and mixtures thereof, optionally wherein the hyaluronate is sodium hyaluronate.

11. The emulsion of claim 10, wherein the emulsion comprises hyaluronic acid and / or hyaluronate in an amount of at least about 0.01% by weight, for example about 0.1% to about 0.4%.

12. The emulsion of any preceding claim, wherein the at least one semifluorinated alkane comprises F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof.

13. The emulsion of any preceding claim, wherein the at least one semifluorinated alkane comprises F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, F6H10 or any combination thereof.

14. The emulsion of any preceding claim, wherein the at least one semifluorinated alkane is selected from F4H5, F6H8, or a combination thereof.

15. The emulsion of any preceding claim, wherein the at least one semifluorinated alkane comprises F6H8, optionally wherein the organic phase is substantially free of other semifluorinated alkanes.

16. The emulsion of any preceding claim, wherein F6H8 is the only semifluorinated alkane in the organic phase.

17. The emulsion of any preceding claim, wherein the emulsion comprises about 0.05% to about 10% by weight of the organic phase, for example about 0.1% to about 5% by weight of the organic phase, for example about 0.1 % to about 1 % by weight of the organic phase.

18. The emulsion of any preceding claim, wherein the organic phase comprises at least 90% by weight semifluorinated alkane, for example wherein the organic phase consists essentially of semifluorinated alkane.

19. The emulsion of claim 18, wherein the organic phase comprises at least 90% by weight F6H8, for example wherein the organic phase consists essentially of F6H8.

20. The emulsion of any preceding claim, wherein the emulsion does not include polyquaternium-1.

21. The emulsion of any one of claims 1 -17 or 20, wherein the organic phase additionally comprises at least one ophthalmically acceptable oil, preferably wherein the ophthalmically acceptable oil is selected from triglycerides and mineral oil, for example a medium-chain triglyceride.

22. The emulsion of claim 21 , wherein the at least one ophthalmically acceptable oil and the at least one semifluorinated alkane are present in the organic phase at a weight ratio of about 1 :1 to about 4:1 , for example about 3:1.

23. The emulsion of claim 21 or claim 22, wherein the organic phase has a density of about 1.0 to about 1.1 g / cm324. The emulsion of any preceding claim for use in a method for the treatment or temporary prevention of at least one ocular disorder, wherein the method comprises administering to a patient in need thereof an effective amount of said emulsion.

25. The emulsion for use according to claim 24, wherein the at least one ocular disorder is dry eye disease, optionally evaporative dry eye disease, aqueous deficient dry eye disease, or both.-si-26. The emulsion for use according to claim 24 or claim 25, wherein the ophthalmic composition is administered in the form of eye drops.

27. A container closure system for dispensing an ophthalmic composition containing the emulsion of any one of claims 1 -23.

28. The container closure system of claim 27, wherein the container closure system comprises a) a bottle or vial and b) a dropper outlet for application of the emulsion to the eye.

29. A process for preparing the emulsion of any one of claims 1-23, comprising mixing the organic phase with the aqueous phase and emulsifying the organic phase and aqueous phase using high shear homogenization, preferably at between about 1 ,000 rpm and about 20,000 rpm.

30. The process of claim 29, where the high shear homogenization is followed by high pressure homogenization, preferably wherein the high pressure homogenization takes place at a pressure of between about 100 bar and 2,000 bar.